David Young, M.D., Ph.D.

Dr. Young is a board-certified Pediatrician and Pediatric Hematologist and Oncologist who studies the genetics, molecular biology, and clinical management and treatment of bone marrow failure syndromes, myeloid malignancies, and other genetic disorders. He oversees clinical trials in aplastic anemia and Diamond-Blackfan anemia while also working with non-human primate models of disease and preclinical development. He also serves as the Medical Director for the RUNX1 Natural History Program of the National Human Genome Research Institute.

Dr. Young received a B.Sc. from the University of Notre Dame, studying the structure and synthesis of novel antineoplastic agents isolated from natural sources, while also working as a laboratory assistant examining the effects of dietary phytoestrogens in a rat model of prostate cancer. He then completed his MD and PhD in Cancer Biology at the University of Chicago studying the genetics and molecular biology of the therapy-related myeloid neoplasms. After a pediatric internship and residency at Hasbro Children’s Hospital of the Brown University Alpert School of Medicine, he trained in the joint Johns Hopkins-NIH Pediatric Hematology/Oncology Fellowship where he studied the biology and treatment of FLT3-mutated acute myeloid leukemia. He joined the Translational Stem Cell Biology Branch of the National Heart, Lung, and Blood Institute in 2018 where he has developed preclinical, non-human primate models for cellular therapeutics, marrow diseases. He also conducts laboratory research into hematopoiesis and marrow failure.

Publications

Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag

Long-term eltrombopag for bone marrow failure depletes iron

Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis

Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions